Chemomab Therapeutics
CMMB
14 hedge funds and large institutions have $2.44M invested in Chemomab Therapeutics in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
18% more capital invested
Capital invested by funds: $2.07M → $2.44M (+$368K)
8% more funds holding
Funds holding: 13 → 14 (+1)
0% more ownership
Funds ownership: 0.23% → 0.23% (+0%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$54K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$13K |
| 3 |
Morgan Stanley
New York
|
+$3.81K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$1.08K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$865 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$20.4K |
| 2 |
Two Sigma Advisers
New York
|
-$17K |
| 3 |
Two Sigma Investments
New York
|
-$13.5K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8.94K |
| 5 |
O
OrbiMed
New York
|
-$3 |
CMMB Hedge Fund Activity: Q2 2024 in Review
14 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q2 2024, worth a combined $2.44M — up 18% from $2.07M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CMMB positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $54K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $20.4K sold.
- 14 institutional investors held Chemomab Therapeutics (CMMB) as of Q2 2024, up from 13 in Q1 2024.
- Funds reported $2.44M of Chemomab Therapeutics stock for Q2 2024, up 18% quarter-over-quarter.
- 3 funds opened new Chemomab Therapeutics positions in Q2 2024 and 2 closed out, a net change of +1 holder.
- The largest Chemomab Therapeutics buyer in Q2 2024 was Citadel Advisors, an estimated $54K added.
- The largest Chemomab Therapeutics seller in Q2 2024 was Two Sigma Securities, an estimated $20.4K sold.
Based on aggregated 13F filings for Q2 2024.